CA3019012A1 - Methods of using (2r, 6r)-hydroxynorketamine and (2s, 6s)-hydroxynorketamine in the treatment of depression, anxiety, anhedonia, fatigue, suicidal ideation, and post traumatic stress disorders - Google Patents
Methods of using (2r, 6r)-hydroxynorketamine and (2s, 6s)-hydroxynorketamine in the treatment of depression, anxiety, anhedonia, fatigue, suicidal ideation, and post traumatic stress disorders Download PDFInfo
- Publication number
- CA3019012A1 CA3019012A1 CA3019012A CA3019012A CA3019012A1 CA 3019012 A1 CA3019012 A1 CA 3019012A1 CA 3019012 A CA3019012 A CA 3019012A CA 3019012 A CA3019012 A CA 3019012A CA 3019012 A1 CA3019012 A1 CA 3019012A1
- Authority
- CA
- Canada
- Prior art keywords
- disorder
- hnk
- ketamine
- anxiety
- hydroxynorketamine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662313317P | 2016-03-25 | 2016-03-25 | |
| US62/313,317 | 2016-03-25 | ||
| PCT/US2017/024238 WO2017165877A1 (en) | 2016-03-25 | 2017-03-27 | Methods of using (2r, 6r)-hydroxynorketamine and (2s, 6s)-hydroxynorketamine in the treatment of depression, anxiety, anhedonia, suicidal ideation, and post traumatic stress disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3019012A1 true CA3019012A1 (en) | 2017-09-28 |
Family
ID=58530652
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3019012A Abandoned CA3019012A1 (en) | 2016-03-25 | 2017-03-27 | Methods of using (2r, 6r)-hydroxynorketamine and (2s, 6s)-hydroxynorketamine in the treatment of depression, anxiety, anhedonia, fatigue, suicidal ideation, and post traumatic stress disorders |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20190083420A1 (cg-RX-API-DMAC10.html) |
| EP (1) | EP3432869A1 (cg-RX-API-DMAC10.html) |
| JP (1) | JP2019512528A (cg-RX-API-DMAC10.html) |
| CN (1) | CN109475514A (cg-RX-API-DMAC10.html) |
| AU (1) | AU2017238858A1 (cg-RX-API-DMAC10.html) |
| CA (1) | CA3019012A1 (cg-RX-API-DMAC10.html) |
| WO (1) | WO2017165877A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3043785T3 (da) | 2013-09-13 | 2021-11-15 | Univ Chiba Nat Univ Corp | Anvendelse af r-ketamin og salt deraf som lægemidler |
| CN107847469A (zh) | 2015-06-27 | 2018-03-27 | 美国神农制药责任有限公司 | 氯胺酮透皮递送系统 |
| AU2017238859B2 (en) | 2016-03-25 | 2021-02-18 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Crystal forms and methods of synthesis of (2R, 6R)-hydroxynorketamine and (2S, 6S)-hydroxynorketamine |
| AU2017250086A1 (en) * | 2016-04-11 | 2018-09-20 | Clexio Biosciences Ltd. | Deuterated ketamine derivatives |
| WO2018102488A1 (en) * | 2016-11-30 | 2018-06-07 | Wolfson Philip E | Ketamine for the treatment of menstrually related symptoms |
| DK3505157T3 (da) | 2017-12-29 | 2022-02-28 | Celon Pharma Sa | Tørpulver-ketaminsammensætning til pulmonal indgivelse ved behandlingsresistent depression |
| WO2019160057A1 (ja) | 2018-02-15 | 2019-08-22 | 国立大学法人千葉大学 | 炎症性疾患若しくは骨疾患の予防又は治療剤及び医薬組成物 |
| CN110343050B (zh) * | 2018-04-04 | 2021-09-24 | 上海键合医药科技有限公司 | 芳香类化合物及其制备方法和用途 |
| CN118121577A (zh) | 2018-05-04 | 2024-06-04 | 感知神经科学公司 | 治疗物质滥用的方法 |
| WO2020237748A1 (zh) * | 2019-05-24 | 2020-12-03 | 北京大学深圳研究生院 | 一种长效化合物的制备方法 |
| EP4007575B1 (en) * | 2019-11-05 | 2023-09-27 | Claes THULIN | 4-[5-[(rac)-1-[5-(3-chlorophenyl)-3-isoxazolyl]ethoxy]-4-methyl-4h-1,2,4-triazol-3-yl]pyridine for use in prevention and/or treatment of stress |
| CN113125586B (zh) * | 2019-12-31 | 2022-05-24 | 成都百裕制药股份有限公司 | 一种1-[2-(2，4-二甲基-苯硫基)-苯基]哌嗪及其异构体的检测方法 |
| EP4168385A4 (en) | 2020-06-17 | 2024-07-17 | Spirify Pharma Inc. | HYDROXYNORKETAMINE ANALOGS, COMPOSITIONS COMPRISING THEM AND METHODS OF USE THEREOF |
| US12466785B2 (en) | 2020-08-31 | 2025-11-11 | Shenzhen Ruijian Biotechnology Co., Ltd | Long-acting low-addiction HNK derivative and preparation method therefor |
| CN112516130B (zh) * | 2020-08-31 | 2022-01-04 | 深圳瑞健生物科技有限公司 | 一种长效低成瘾性化合物在制备药物中的应用 |
| KR102906446B1 (ko) | 2020-08-31 | 2026-01-02 | 선전 루이지엔 바이오테크놀로지 컴퍼니 리미티드 | 장기 작용성 및 저중독성 hnk 유도체 및 그의 제조 방법 |
| CN112521357B (zh) * | 2020-08-31 | 2021-10-08 | 深圳瑞健生物科技有限公司 | 一种长效低成瘾性hnk衍生物及其制备方法 |
| CN114524737B (zh) * | 2020-11-23 | 2024-10-22 | 江苏恒瑞医药股份有限公司 | 一种取代的环己酮类化合物 |
| CN114947839B (zh) * | 2022-05-27 | 2025-12-02 | 华东师范大学 | 大脑调控的训练方法、装置及电子设备 |
| CN120736994B (zh) * | 2025-01-26 | 2025-11-18 | 上海东西智荟生物医药有限公司 | 氯胺酮衍生物及其在精神疾病的治疗中的用途 |
| CN121313626A (zh) * | 2025-10-27 | 2026-01-13 | 北京大学深圳研究生院 | 治疗胶质母细胞瘤的化合物和方法 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6296985B2 (ja) * | 2011-10-14 | 2018-03-20 | ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ | うつ病及び神経障害性疼痛の治療における（２ｒ，６ｒ）−ヒドロキシノルケタミン、（ｓ）−デヒドロノルケタミン及び他の（ｒ，ｓ）−ケタミンの立体異性デヒドロ及びヒドロキシル化代謝生成物の使用 |
| US20140079740A1 (en) * | 2012-08-02 | 2014-03-20 | ClinPharm Support GmbH | Oral transmucosal adminstration forms of s-ketamine |
-
2017
- 2017-03-27 US US16/088,294 patent/US20190083420A1/en not_active Abandoned
- 2017-03-27 WO PCT/US2017/024238 patent/WO2017165877A1/en not_active Ceased
- 2017-03-27 AU AU2017238858A patent/AU2017238858A1/en not_active Abandoned
- 2017-03-27 JP JP2018550327A patent/JP2019512528A/ja active Pending
- 2017-03-27 CN CN201780029039.8A patent/CN109475514A/zh active Pending
- 2017-03-27 EP EP17716697.2A patent/EP3432869A1/en not_active Withdrawn
- 2017-03-27 CA CA3019012A patent/CA3019012A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU2017238858A1 (en) | 2018-10-18 |
| US20190083420A1 (en) | 2019-03-21 |
| CN109475514A (zh) | 2019-03-15 |
| EP3432869A1 (en) | 2019-01-30 |
| WO2017165877A1 (en) | 2017-09-28 |
| JP2019512528A (ja) | 2019-05-16 |
| WO2017165877A8 (en) | 2018-10-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20190083420A1 (en) | Methods of using (2r, 6r)-hydroxynorketamine and (2s, 6s)-hydroxynorketamine in the treatment of depression, anxiety, anhedonia, fatigue, suicidal ideation, and post traumatic stress disorders | |
| JP2026053405A (ja) | 中枢神経系障害の治療のためのセロトニン作動性幻覚薬としてのシロシン誘導体 | |
| JP7514534B2 (ja) | 認知障害を処置するためのベンゾジアゼピン誘導体、組成物および方法 | |
| AU2016323977B9 (en) | Carboxylic diarylthiazepineamines as mu-opioid receptor agonists | |
| JP2016519091A (ja) | 新規抗がん剤としてのキノリン誘導体 | |
| US11787772B2 (en) | Carboxylic diarythiazepineamines as mixed mu- and delta-opioid receptor agonists | |
| WO2005102390A2 (en) | Combinations comprising alpha-2-delta ligands and nmda receptor antagonists | |
| CN112930175A (zh) | 治疗癫痫的方法 | |
| JP2025501410A (ja) | 重水素化有機化合物およびその使用 | |
| US12606523B2 (en) | Deuterated organic compounds and uses thereof | |
| JP2023133571A (ja) | 気分障害のための新規ガンマアミノ酪酸型受容体モジュレーター | |
| WO2023081895A1 (en) | Isotopically enriched analogs of 5,6-methylenedioxy-2-aminoindane (mdai) | |
| US20240207265A1 (en) | TREATMENT OF CNS DISEASES WITH sGC STIMULATORS | |
| WO2022074589A1 (en) | Carboxylic diarylthiazepineamines and uses therefor | |
| WO2016138103A1 (en) | Treatments for alzheimer's related diseases and disorders | |
| CN120736994A (zh) | 氯胺酮衍生物及其在精神疾病的治疗中的用途 | |
| WO2011028571A1 (en) | Taxane analogues, their use, pharmaceutical compositions containing them, and processes for their preparation | |
| IL317344A (en) | Substances and their use for the treatment of mental or neurological diseases | |
| CN112521357B (zh) | 一种长效低成瘾性hnk衍生物及其制备方法 | |
| TW201811761A (zh) | 用於治療用途之化合物 | |
| RU2667954C2 (ru) | Фармацевтическая композиция для лечения функциональных психических расстройств | |
| HK40045266A (en) | Method for treating epilepsy | |
| JP2022510362A (ja) | Ｒ－２－（置換スルホニル）－ヘキサヒドロ－ピロロ［１，２－ａ］ピラジン－６（２Ｈ）－オンとＳ－２－（置換スルホニル）－ヘキサヒドロ－ピロロ［１，２－ａ］ピラジン－６（２Ｈ）－オンを非ラセミ比で含む相乗的組成物 | |
| HK40009154B (en) | Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use | |
| HK40009151A (en) | Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |
Effective date: 20230627 |